Silexion Therapeutics shares surge 52.39% intraday after announcing new preclinical data showing 97% inhibition in pancreatic cancer cells and 90% in colorectal cancer cells with its RNA interference therapy SIL204.

Silexion Therapeutics Corp. surged 52.39% intraday after announcing new preclinical data showing its RNA interference therapy SIL204 achieved a 97% inhibition rate in pancreatic cancer cells and a 90% inhibition rate in colorectal cancer cells, and demonstrated efficacy against KRAS Q61H mutation for the first time. The company is a clinical-stage biotechnology firm focused on developing RNA interference therapies targeting KRAS-driven cancers, with SIL204 as its lead candidate for pancreatic cancer treatment.